APA (7th ed.) Citation

J, T., SC, M., F, G., E, H., M, N., JP, H., . . . FR, G. (2026). Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study. Clinical pharmacology and therapeutics. https://doi.org/10.1002/cpt.70367

Chicago Style (17th ed.) Citation

J, Tachet, et al. "Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study." Clinical Pharmacology and Therapeutics 2026. https://doi.org/10.1002/cpt.70367.

MLA (9th ed.) Citation

J, Tachet, et al. "Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study." Clinical Pharmacology and Therapeutics, 2026, https://doi.org/10.1002/cpt.70367.